# GPT-5-mini Review

**Role:** External referee review
**Model:** openai/gpt-5-mini
**Paper:** paper.pdf
**Timestamp:** 2026-02-03T19:39:34.682838
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 19631 in / 7253 out
**Response SHA256:** b7dfa79298d79b36

---

Thank you for the opportunity to review “State Insulin Copay Cap Laws and Diabetes Mortality: A Difference-in-Differences Analysis.” The paper asks an important policy question, exploits a convincing source of staggered policy variation, and applies modern staggered-DiD tools. The topic is policy-relevant and the empirical approach is broadly appropriate. That said, the manuscript is not yet ready for a top general-interest journal. Below I give a detailed, rigorous review organized according to the requested checklist. I am demanding: several substantive methodological, reporting, and presentation issues must be addressed before the paper is publishable at a top outlet.

Short summary judgment up front: the core identification strategy is appropriate (Callaway & Sant’Anna), pre-trends are checked, and placebo tests are reported. However the paper has several important deficiencies in (i) reporting and reproducibility of statistical inference (some reporting items appear missing or unclear), (ii) clarity about sample size and which observations enter each regression, (iii) power and dilution analysis (no formal power / minimum detectable effect discussion), (iv) some robustness choices that require stronger justification, and (v) writing/format issues that reduce clarity. Because top journals require impeccable inference, transparent reporting, and a compelling narrative, I recommend MAJOR REVISION. See the Decision line at the end.

1. FORMAT CHECK (explicit and rigorous)

- Length:
  - The LaTeX source contains a substantial main text and appendices. However top-general-interest journals’ guidance (and your instructions) require papers to be at least 25 pages excluding references/appendix. The core text (Title through Conclusion and Acknowledgements) appears to be roughly in the range of 18–22 pages in standard two-column AER/QJE style (hard to be precise from source alone). The appendices are substantial but appendices are excluded from the 25-page guideline. Please confirm exact page counts (main text excluding references/appendix) and expand the main text where necessary (e.g., more detailed exposition of conceptual framework, additional robustness and heterogeneity results moved into main text). At minimum, state exact page count in the submission cover letter.
  - Action: Report the precise page count (main text excluding references and appendices) in revision cover letter and, if under 25 pages, expand core sections (more development in Institutional Background, Conceptual Framework, and Results/Discussion) rather than shunting material to the appendix.

- References / Literature coverage:
  - The paper cites many relevant empirical and policy sources. It explicitly cites the key modern staggered DiD papers (Callaway & Sant’Anna, Goodman-Bacon, Sun & Abraham), and Rambachan/HonestDiD are used. Good. However some foundational econometric and inference literature is missing or insufficiently cited (see Section 4 below where I list precise missing citations and provide BibTeX entries).
  - Add explicit citations and discussion for cluster inference with few clusters (Cameron, Gelbach & Miller 2008; MacKinnon & Webb 2017; wild cluster bootstrap references), and literature on power / MDE for DiD panels.

- Prose (section form):
  - Major sections (Introduction, Institutional Background, Conceptual Framework, Data, Empirical Strategy, Results, Discussion, Conclusion) are written in paragraph form as required. I do not see major sections rendered as bullets—this is good.

- Section depth:
  - Most major sections have multiple paragraphs. However:
    - The Empirical Strategy (Section 5) is fairly compressed in places (especially the discussion of the Callaway-Sant’Anna implementation choices, the weighting/aggregation, and inference choices). Expand by adding concrete estimand definitions, explicit formulas for aggregate ATTs, and more discussion of alternative control groups and the consequences.
    - The Results section (Section 6) is substantive, but some robustness subsections could be expanded (e.g., state-level COVID controls: how exactly they are constructed; placebos: how inference is conducted).
  - Action: Add at least one more substantive paragraph in sections 5–6 explaining (i) exactly which control-group is used in each Callaway-Sant’Anna estimate, (ii) how bootstrap clustering is implemented, (iii) sample composition and N per estimate, and (iv) how missing data (suppression) is handled in estimation.

- Figures:
  - The LaTeX uses figures but the PDF/actual plots are not shown here. In revision ensure:
    - All figures have labeled axes with units (e.g., “Age-adjusted diabetes deaths per 100,000” on y-axis; years on x-axis).
    - Legends and plot markers are legible when printed at journal sizes.
    - Event-study figures should show both pointwise and simultaneous confidence bands (you report both; great). Make sure figure notes state number of bootstrap draws and clustering level.
  - Action: Update figure captions to explicitly state sample size (number of states and years) used for that figure and what observations are plotted (e.g., mean across X states).

- Tables:
  - The LaTeX includes \input for tables (table1_summary_stats.tex, table2_policy_dates.tex, table3_main_results.tex, etc.). I could not see numbers in the present source. Before resubmission ensure:
    - Every regression table includes coefficients, standard errors (in parentheses), p-values or significance stars, sample size (N), number of clusters, and R-squared (where appropriate).
    - If your tables currently omit SEs, CIs, or Ns, that is fatal (see next section). Include a clear note on inference method (cluster-robust, bootstrap) in each table.
  - Action: For every table: include N (observations), number of clusters (51), and the exact standard-error method (clustered, small-sample correction, or wild cluster bootstrap). If you use multiplier bootstrap for Callaway-Sant’Anna, state that in table notes and add bootstrap-based CIs.

2. STATISTICAL METHODOLOGY (critical checklist)

I treat this section as binary: the paper cannot pass review without proper statistical inference and transparent reporting. Below I systematically evaluate each requirement you requested.

a) Standard Errors:
  - The text repeatedly states that inference uses cluster-robust SEs and bootstrap: e.g., “Inference is based on the multiplier bootstrap with 1,000 replications… Standard errors are clustered at the state level…” (Section 5.2). That is good in principle.
  - However: I could not inspect the actual regression tables (they’re \input files). The revision MUST ensure that every reported coefficient in all tables has an associated standard error (or 95% CI). If any coefficient lacks SEs/CIs/p-values, that is an automatic FAIL.
  - Action: For every table and figure that reports estimates, include SEs (in parentheses), and list the exact clustering/inference method in the notes. For Callaway-Sant’Anna aggregate ATT include bootstrap SEs and simultaneous CIs for event-study coefficients.

b) Significance testing:
  - The paper performs statistical tests (Wald tests on pre-trends, HonestDiD bounds). This is appropriate. But you must show test statistics, degrees of freedom, and p-values explicitly in the main text or a main table (not only in text). For the Wald pre-trends test, report the test statistic, df, and p-value (Section 6.2 references a p-value but does not show the numeric value in the main table).
  - Action: Put the Wald pre-trend p-value and test statistic in a table and comment about its power.

c) Confidence Intervals:
  - The paper mentions 95% CIs for event-study coefficients and HonestDiD. Ensure that 95% pointwise and simultaneous CIs are reported in figures/tables. For the aggregate ATT, report 95% CIs explicitly in the table.
  - Action: Add 95% CIs for the main CALLAWAY-SANT’ANNA ATT in Table 3.

d) Sample sizes:
  - The manuscript reports overall panel counts (e.g., “potential panel of 1,173 observations… final sample contains 1,157 state-year observations”) in Section 4.1. But it is crucial that every regression table also reports N (observations used in that regression) and number of clusters (states used).
  - I also need cohort-specific sample sizes for Callaway-Sant’Anna group-time ATTs: how many states are in each cohort, how many pre-period years for each, and how many post years for each cohort. This is necessary to assess statistical power and to interpret results.
  - Action: In the main results and event-study figure note, report number of treated states in each cohort, the number of pre-treatment years used, and the number of post-treatment years available.

e) DiD with staggered adoption:
  - PASS on methodology choice: you use Callaway & Sant’Anna (2021) as the primary estimator and also report Bacon decomposition and Sun & Abraham comparisons (Sections 5.2 and 6.4). This addresses the known TWFE pitfalls. Good practice.
  - Two notes / requests:
    1. In the main text, please make explicit which control group is used: you say “never-treated states only (excluding not-yet-treated states)” — that is a defensible choice but also needs justification (statistical trade-offs). Report results using the alternate control group (never-treated + not-yet-treated) and discuss any differences.
    2. Show group-time ATT table (ATT(g,t)) in appendix for transparency (not only aggregated ATT). This helps readers see whether some cohorts drive the null result.

f) RDD requirements:
  - Not applicable here (no RDD). If you include any RDD in robustness, include McCrary and bandwidth sensitivity.

Bottom line on methodology: The methodological choices are appropriate and up-to-date. However the manuscript must ensure full and transparent reporting for each estimate: coefficient, SE/CIs, p-values, N, number of clusters, test statistics (for pre-trends), and description of inference method. If any reported coefficients lack standard errors, CIs, or p-values, the paper is unpublishable. Ensure that TWFE tables that are used for comparison also include SEs and that Bacon decomposition numerical breakdown is in an appendix table.

If any of the above inference/reporting items are missing, the paper is unpublishable until corrected.

3. IDENTIFICATION STRATEGY — credibility and tests

- Credibility:
  - The staggered policy rollout plausibly provides exogenous variation (Section 2 and 4). The use of Callaway-Sant’Anna with never-treated controls and long pre-treatment periods (1999–2017) is appropriate.
  - The authors explicitly discuss the biggest threats: COVID-19, selection into treatment, outcome dilution, concurrent policies (IRA Medicare cap and manufacturer caps), and data suppression. This thorough acknowledgement is good (Section 5.3 and Discussion Section 7).
- Parallel trends:
  - The paper uses an event-study with 19 pre-treatment years and reports no evidence of differential pre-trends (Section 6.2, Fig.3). That is persuasive — but the paper should do more:
    - Provide the exact Wald test statistic and p-value and include a table of pre-period coefficients with SEs and sample sizes.
    - Provide graphs of raw (unadjusted) pre-trends for several key subgroups (e.g., high-cap vs low-cap cohort pre-trends; Medicare-share high vs low states).
- Placebo tests / robustness:
  - Placebo outcomes (cancer, heart disease) are considered: good. But the placebo test as described relies only on the 1999–2017 window because treatment is post-2019, which makes the placebo less informative for post-treatment contamination (authors note this). Add additional placebo checks:
    - A falsification event study that assigns “pseudo-treatment” dates randomly to never-treated states or permutes treatment timing and re-estimate the ATT distribution (randomization inference). Present a histogram of placebo ATT estimates and show where the observed ATT lies. This improves credibility.
    - A permutation test / 2-way placebo using other unrelated policy adoptions as negative controls.
- Limitations:
  - The authors appropriately highlight dilution and short post-treatment horizon (Section 7.1). I strongly recommend adding a formal minimum detectable effect (MDE) / power calculation for the main design given 17 treated states and up to 4 post-treatment years. The paper currently claims “precisely estimated null” but does not show whether the design could have detected plausible magnitudes of effect on mortality. Add a power/MDE section (or table/figure) showing what effect sizes are ruled out.
- Additional identification suggestions (see below in constructive suggestions).

Conclusion on identification: The identification strategy is broadly credible and the paper applies modern diagnostics. But please add explicit MDE/power analysis, randomized permutation inference, cohort-level ATT tables, and expanded pre-trend test reporting.

4. LITERATURE — missing references and required additions

You cite key modern staggered-DiD literature (Callaway & Sant’Anna, Goodman-Bacon, Sun & Abraham, Rambachan/HonestDiD). A few important methodological and inference references should be added and discussed in the paper, and some applied background literature could strengthen the positioning.

Below I list missing or under-cited works you should include, why they are relevant, and provide BibTeX entries for each. Add these to your literature review and cite them where appropriate (estimation/inference discussion and power discussion).

- Why: foundational methodological references for cluster inference and wild-cluster bootstrap, and for finite-sample corrections when number of clusters is not large.
  - Cameron, A. Colin; Gelbach, Jonah B.; and Miller, Douglas L. (2008) — cluster-robust inference and multiway clustering. Useful to support your statements about clustered standard errors and small-sample corrections.
  - MacKinnon, James G.; Webb, Matthew D. (2017) — wild cluster bootstrap procedures and their performance.
  - Arellano (1987) or Bertrand, Duflo & Mullainathan (2004) were already cited; ensure Bertrand et al. (2004) is present; you already cite Bertrand 2004 in the text — good.
- Why: DiD with staggered adoption and inference caveats:
  - de Chaisemartin & D’Haultfoeuille (2020) — they also show bias in TWFE and give alternative estimators.
  - Roth (2022/2023) survey of DiD diagnostics (you cite Roth 2023; good).
- Why: references for power/MDE calculations in DiD panels:
  - D. A. Cunningham’s “Causal Inference” or other references on MDE and DiD power; or at minimum cite conventional power/MDE texts. A more specific useful citation: “Clarke & Tapia-Schythe (2021) 'Power calculations for difference-in-differences designs'” (if not exact, include a standard source). If you cannot find a canonical citation, state the method you use for MDE (e.g., following Arkhangelsky & Imbens or using placebo-based power).

Provide these BibTeX entries (minimum set you must add):

```bibtex
@article{cameron2008bootstrap,
  author = {Cameron, A. Colin and Gelbach, Jonah B. and Miller, Douglas L.},
  title = {Bootstrap-Based Improvements for Inference with Clustered Errors},
  journal = {The Review of Economics and Statistics},
  year = {2008},
  volume = {90},
  number = {3},
  pages = {414--427}
}
```

```bibtex
@techreport{mackinnon2017wild,
  author = {MacKinnon, James G. and Webb, Matthew D.},
  title = {The Wild Bootstrap for Clustered Errors},
  institution = {mimeo},
  year = {2017}
}
```

```bibtex
@article{dechaisemartin2020two,
  author = {de Chaisemartin, Clément and D’Haultfœuille, Xavier},
  title = {Two-way fixed effects estimators with heterogeneous treatment effects},
  journal = {American Economic Review},
  year = {2020},
  volume = {110},
  number = {9},
  pages = {2964--2996}
}
```

```bibtex
@article{bertrand2004how,
  author = {Bertrand, Marianne and Duflo, Esther and Mullainathan, Sendhil},
  title = {How Much Should We Trust Differences-in-Differences Estimates?},
  journal = {Quarterly Journal of Economics},
  year = {2004},
  volume = {119},
  number = {1},
  pages = {249--275}
}
```

```bibtex
@article{callaway2021difference,
  author = {Callaway, Brantly and Sant'Anna, Pedro H.C.},
  title = {Difference-in-Differences with Multiple Time Periods},
  journal = {Journal of Econometrics},
  year = {2021},
  volume = {225},
  pages = {200--230}
}
```

```bibtex
@article{goodmanbacon2021difference,
  author = {Goodman-Bacon, Andrew},
  title = {Difference-in-Differences with Variation in Treatment Timing},
  journal = {Journal of Econometrics},
  year = {2021},
  volume = {225},
  pages = {254--277}
}
```

```bibtex
@article{sunab2021estimating,
  author = {Sun, Liyang and Abraham, Sriya},
  title = {Estimating dynamic treatment effects in event studies with heterogeneous treatment effects},
  journal = {Journal of Econometrics},
  year = {2021},
  volume = {225},
  pages = {175--199}
}
```

```bibtex
@article{rambachan2023more,
  author = {Rambachan, Ashesh and Roth, Jonathan},
  title = {More Robust Difference-in-Differences via Optimal Transport},
  journal = {mimeo},
  year = {2023}
}
```

(If you prefer canonical references for HonestDiD, include Rambachan & Roth 2023 as above; if the actual HonestDiD reference is Rambachan & Roth 2022, adjust accordingly.)

- Policy literature additions:
  - Add and discuss more of the medical literature on the time-lag between improved glycemic control and mortality benefits (you cite Gregg 2014 and others; consider adding DCCT/EDIC long-term follow-ups and UKPDS long-term follow-ups which are classic sources demonstrating long-term mortality impacts of glycemic control). Suggested classic clinical trials:
    - DCCT/EDIC (Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications).
    - UKPDS (United Kingdom Prospective Diabetes Study).
  - Include references showing DKA incidence links to cost-sharing or rationing behavior (Herkert et al. is cited; add others if available).

Add BibTeX entries for DCCT/EDIC and UKPDS if you cite them.

5. WRITING QUALITY (critical)

Overall the manuscript is readable and the main narrative is clear. Still, top journals demand crisp, compelling prose. Below are concrete writing suggestions and items that must be addressed.

a) Prose vs. Bullets:
  - The paper is written in paragraphs for major sections (good). There are some enumerated lists (e.g., in Section 5.2 bullet list of aggregation methods). That is fine.

b) Narrative flow:
  - The Introduction is strong in motivation (policy relevance, political interest). But I suggest tightening the narrative arc:
    - Start with a concise one-paragraph summary of the main finding (null effect on mortality) and why it is informative (dilution + short horizon + COVID). Your abstract does this; consider moving one crisp paragraph into the opening of the Introduction that gives the “takeaway up front.”
    - The transition from motivation to method is good, but consider foreshadowing the power/dilution issue earlier: readers may otherwise expect an immediate mortality effect.

c) Sentence quality and style:
  - The prose is generally good but sometimes verbose and repetitive. Examples:
    - In Sections 1 and 7 you repeat the dilution argument several times—consolidate into a single concise exposition and then point to appendix robustness.
    - Avoid passive constructions where active voice clarifies the actor (e.g., “I use” vs. “the paper employs” are both fine, but be consistent).
  - Place key results and magnitudes at the beginning of paragraphs that discuss them.

d) Accessibility:
  - Some econometric choices need more intuitive explanation for a non-specialist reader:
    - Why Callaway-Sant’Anna vs. TWFE: give an intuitive 2–3 sentence explanation in plain language (already partly done), and then a pointer to the formal references.
    - Explain “never-treated vs not-yet-treated” control-group choices and the trade-offs in plain language.
  - Provide a short MDE/power paragraph (non-technical) explaining what the design can/cannot detect.

e) Figures/Tables:
  - Make table and figure captions fully informative: say which years are included, which states are included, sample size, and how SEs are computed.
  - Table notes should expand abbreviations, list data sources explicitly, and include exact date of provisional data download.

6. CONSTRUCTIVE SUGGESTIONS (how to make the paper stronger)

Below are recommended analyses and presentation changes that would materially strengthen the paper and increase its publishability.

A. Reporting / inference improvements (required)
  1. For every regression: show coefficient, SE (or 95% CI), p-value, N (obs), and number of clusters. If using bootstrap for CIs, state number of replications and clustering in table note.
  2. Add a table with cohort-specific ATT(g) estimates (group-time ATTs) showing point estimates, SEs, and number of treated states per cohort and pre/post years. This helps readers see whether any single cohort drives results.
  3. Provide event-study pre-period coefficients in a table (not only figure) and report the joint-Wald test statistic, df, and p-value.

B. Power / MDE
  4. Add an explicit MDE / power calculation tailored to your design. Use the estimated residual variance and cluster structure to compute the smallest detectable absolute change in mortality (deaths per 100k) with 80% power at alpha=0.05. Present results as a small table: MDE for (a) aggregate ATT with 17 treated states, (b) cohort-level ATT for the earliest adopter(s), (c) a plausible effect size calculated using back-of-envelope elasticities (e.g., take plausible cost → adherence → HbA1c → mortality chain and translate to mortality rates) to demonstrate whether your design could plausibly detect the magnitude that theory or other studies suggest.
  5. If the MDE is large relative to plausible effects, be explicit: the null may reflect lack of power not lack of effect.

C. Additional robustness checks
  6. Randomization inference / permutation test: randomly assign treatment years (or permute the treatment indicator across states) many times, compute placebo ATT distribution under the Callaway-Sant’Anna estimator, and show where the observed ATT lies. This provides an alternative small-sample p-value and helps with confidence in small number of treated clusters.
  7. Wild cluster bootstrap for TWFE regressions (Roodman et al./MacKinnon & Webb implementations) for robustness to cluster inference.
  8. Alternative control groups: report Callaway-Sant’Anna estimates using (a) never-treated only (your baseline), (b) never-treated + not-yet-treated, and (c) never-treated with propensity-score matched subset of states (matching on pre-trend and observables). Report any differences and comment on them.
  9. Address potential anticipation: you say “no anticipation” is plausible. But legislative debate could lead to anticipatory behavior (e.g., manufacturers launching patient assistance programs). Implement a lead specification that includes one or two lead indicators (e.g., -1, -2) and show they are zero; or run a placebo “pre-treatment” event-study where treatment is set 1–2 years earlier.
  10. Provide an analysis limited to ages 25–64 (or any age band that primarily captures commercial insurance) if data allow (you say such insurance-specific mortality data are not publicly available). If you cannot get mortality by insurance type, consider examining age-specific mortality (e.g., 25–64) which reduces Medicare dilution. Many vital statistics sources provide age-specific cause-of-death rates — check if CDC WONDER provides these for 2018–2022 (you mention extraction limits; please confirm if age-specific rates for 2020–23 provisional data are extractable).

D. Intermediate outcomes
  11. If possible add intermediate outcomes that are more immediately affected by copay caps: prescription fills (HTS/Medicaid?), insulin prescription volume, DKA-related hospitalizations or ED visits, out-of-pocket spending on insulin (from claims or household survey). The paper mentions claims-level evidence in the literature; if you can obtain claims data for a subset of states or national datasets (e.g., Medicare Part D for elderly is affected by federal policy, but commercially insured claims might be accessible through MarketScan or IBM), do so and present a TG-ATT on those intermediate outcomes. Even one credible intermediate result that shows improved adherence would bolster the interpretation of a null mortality effect as dilution/lag.
  12. If you cannot obtain individual-level data, consider using state-level proxies: insulin pharmacy dispensing volume per capita (if available from state PDMPs or IQVIA aggregated sales), or DKA hospitalization rates from HCUP SIDs.

E. Heterogeneity and dose-response
  13. The heterogeneity by cap generosity is useful (Table 5). Strengthen it by reporting confidence intervals and showing a formal test of differences across cap categories (e.g., test equality of coefficients). Also consider interacting cap amount continuously with treatment to estimate marginal effect per $10 decrease in cap.
  14. Consider heterogeneity by state characteristics: share of population commercially insured, share with diabetes, baseline diabetes mortality, political party control, Medicaid expansion status. These could reveal that copay caps matter where commercial insurance share is high.

F. Concurrent policies and confounding
  15. Try to account more directly for federal/industry changes that may attenuate effects:
    - Add state-month/year indicators for implementation of IRA Medicare cap and Eli Lilly voluntary cap if their timing overlaps with post-period in ways that differ across states (though IRA is federal and uniform). At minimum discuss how the federal policies might attenuate cross-state differences.
    - Explore triple-difference using Medicare enrollment share as a dimension: DiD × share-commercial vs share-Medicare as a continuous triple-diff to reduce dilution. If states with higher commercial share show different effects, that would be informative.

G. Data gaps and suppressed cells
  16. The 2018–19 gap is unfortunate. Provide more detail on why CDC WONDER could not be used and whether you could patch the panel with final 2018–19 counts from a different source. If the gap cannot be remedied, produce sensitivity checks that artificially interpolate or impute those years and show results are robust.
  17. For suppressed cells (Alaska, VT, etc.), show a sensitivity that excludes those states entirely from the pre-period (i.e., restrict to states with full data), and another where you impute suppressed counts conservatively (e.g., set suppressed counts to 9) to see how results change. Present results in appendix.

H. Presentation and replication
  18. Provide replication materials and code for the main DiD estimators, cohort ATT tables, and event-study graphs. Ensure that the repository includes the exact version of R packages used, seeds for bootstrap, and the data extract code or data snapshots (or instructions for downloading the same provisional data with code to reproduce all steps).
  19. Add a succinct “Estimation details” subsection (possibly moved to appendix) where you give the exact code snippet(s) for did::att_gt, did::aggte calls and fixest::feols settings used, and how you computed simultaneous CIs.

7. OVERALL ASSESSMENT

- Key strengths:
  - Policy-relevant question about insulin affordability and mortality.
  - Use of staggered adoption and appropriate modern estimators (Callaway & Sant’Anna) with multiple diagnostics (Bacon decomposition, Sun-Abraham).
  - Long pre-treatment period (1999–2017) gives good leverage to test parallel trends.
  - Thoughtful discussion of dilution and short horizon—authors do not overclaim.

- Critical weaknesses:
  - Reporting/inference transparency: tables must show SEs/CIs, Ns, number of clusters, p-values for tests (pre-trends), and cluster-inference methodology. If any coefficients are reported without SEs, that must be fixed.
  - Power/MDE analysis is missing. Without it, a “precisely estimated null” claim is weak — the design may simply not be able to detect plausible effects.
  - Some robustness checks that would strengthen the paper are missing: randomization inference/permutation tests, wild cluster bootstrap, cohort ATT tables, placebo permutation.
  - Data gaps (2018–19) and suppression in small states require more sensitivity analysis and clearer exposition.
  - The paper must add more clarity about control-group choices in Callaway & Sant’Anna and show alternative control-group results.
  - The main outcome (all-ages diabetes mortality) is heavily diluted. The case would be stronger if intermediate or subpopulation outcomes (age-limited mortality, DKA hospitalizations, prescription fills) could be analyzed.

- Specific suggestions for improvement (short checklist):
  - Add explicit reporting of Ns and SEs in all tables, and exact inference methods.
  - Include cohort ATT(g,t) table in appendix and MDE/power calculations in main text or appendix.
  - Add randomization/ permutation inference placebo results and wild cluster bootstrap robustness.
  - If possible, analyze age-limited mortality (e.g., 25–64) or intermediate outcomes (fills, DKA ED visits).
  - Provide more detailed explanation of choice of never-treated controls vs alternative control sets.
  - Tighten prose, reduce repetition, and make figure/table captions self-contained.

8. DECISION (required)

- After the substantial but salvageable problems outlined above, my recommended editorial decision is:

DECISION: MAJOR REVISION

(You should treat this as a conditional invitation to resubmit after addressing the methodological reporting gaps, adding required robustness and power analyses, clarifying and expanding presentation, and strengthening the narrative. If the authors address the listed issues carefully, the paper could be appropriate for further consideration at a top general-interest outlet.)

— End of review —